Top Proteolysis-targeting chimeric molecules (PROTACs) Companies

Skyquest Technology's expert advisors have carried out comprehensive research and identified these companies as industry leaders in the Proteolysis-targeting chimeric molecules (PROTACs) Market. This Analysis is based on comprehensive primary and secondary research on the corporate strategies, financial and operational performance, product portfolio, market share and brand analysis of all the leading Proteolysis-targeting chimeric molecules (PROTACs) industry players.

Proteolysis-targeting chimeric molecules (PROTACs) Market Competitive Landscape

Global Proteolysis-targeting chimeric molecules (PROTACs) market is characterized by several companies operating in the market, with different levels of market share and specialization. Competition of PROTACs is currently limited, with a few key players dominating the market. Arvinas, a biotech company, has emerged as a leader in the development of PROTACs, with several candidates in preclinical and clinical stages of development. Other companies, such as C4 Therapeutics and Kymera Therapeutics, have also entered the PROTACs space, with multiple candidates in various stages of development. Despite the limited competition, the potential for PROTACs to address previously undruggable targets has garnered significant attention from pharmaceutical companies, leading to numerous partnerships and collaborations in the field. Additionally, the development of PROTACs has spurred interest in related technologies, such as molecular glues and protein degraders, further expanding the competitive landscape of this emerging field.

Top Players in Proteolysis-targeting chimeric molecules (PROTACs) Market

  • Arvinas (USA) 
  • C4 Therapeutics (USA) 
  • Kymera Therapeutics (USA) 
  • Nurix Therapeutics (USA) 
  • Bristol Myers Squibb (USA) 
  • Pfizer (USA) 
  • Sanofi (France) 
  • AstraZeneca (UK) 
  • Roche (Switzerland) 
  • Olema Pharmaceuticals (USA) 
  • Radius Health (USA) 
  • Loxo Oncology (USA) 
  • Amphista Therapeutics (UK) 
  • Monte Rosa Therapeutics (USA) 
  • Dunad Therapeutics (UK) 
  • Ranok Therapeutics (China) 
  • Ubiquigent (UK) 
  • Origami Therapeutics (USA) 
  • Treeline Biosciences (USA) 
  • Entact Bio (USA)

Proteolysis-targeting Chimeric Molecules (PROTACs) Market

REPORT OVERVIEW BUY NOW

REQUEST FOR SAMPLE

Want to customize this report? REQUEST FREE CUSTOMIZATION

FAQs

Global Proteolysis-targeting chimeric molecules (PROTACs) Market size was valued at USD 138.26 Million in 2024 and is poised to grow from USD 152.36 Million in 2025 to USD 331.38 Million by 2033, growing at a CAGR of 10.2% during the forecast period (2026–2033).

Global Proteolysis-targeting chimeric molecules (PROTACs) market is characterized by several companies operating in the market, with different levels of market share and specialization. Competition of PROTACs is currently limited, with a few key players dominating the market. Arvinas, a biotech company, has emerged as a leader in the development of PROTACs, with several candidates in preclinical and clinical stages of development. Other companies, such as C4 Therapeutics and Kymera Therapeutics, have also entered the PROTACs space, with multiple candidates in various stages of development. Despite the limited competition, the potential for PROTACs to address previously undruggable targets has garnered significant attention from pharmaceutical companies, leading to numerous partnerships and collaborations in the field. Additionally, the development of PROTACs has spurred interest in related technologies, such as molecular glues and protein degraders, further expanding the competitive landscape of this emerging field. 'Arvinas (USA) ', 'C4 Therapeutics (USA) ', 'Kymera Therapeutics (USA) ', 'Nurix Therapeutics (USA) ', 'Bristol Myers Squibb (USA) ', 'Pfizer (USA) ', 'Sanofi (France) ', 'AstraZeneca (UK) ', 'Roche (Switzerland) ', 'Olema Pharmaceuticals (USA) ', 'Radius Health (USA) ', 'Loxo Oncology (USA) ', 'Amphista Therapeutics (UK) ', 'Monte Rosa Therapeutics (USA) ', 'Dunad Therapeutics (UK) ', 'Ranok Therapeutics (China) ', 'Ubiquigent (UK) ', 'Origami Therapeutics (USA) ', 'Treeline Biosciences (USA) ', 'Entact Bio (USA)'

One of the major drivers behind the development of PROTACs is the need for increased target specificity in drug design. Conventional small-molecule drugs are often non-specific, and may target multiple proteins, leading to off-target effects and toxicity. PROTACs, on the other hand, are designed to specifically target a single protein or even a specific domain within a protein, reducing the risk of unintended effects. This increased target specificity not only enhances the safety profile of PROTACs but also allows for the development of therapies for diseases that were previously untreatable.

One key market trend in the PROTACs market is the increasing adoption of this technology in drug development. PROTACs offer a new approach to drug development by targeting disease-causing proteins for degradation rather than inhibition. This technology has the potential to provide better therapeutic outcomes, especially in diseases where current treatments have limited efficacy. As a result, there is a growing interest in PROTACs from pharmaceutical companies, academic and research institutions, and contract research organizations. Additionally, there is an increasing focus on research and development, which is expected to drive the growth of the market.

North America is one of the largest markets for PROTACs, with the United States being the dominant country in the region. The market is expected to grow significantly due to the increasing number of biotechnology and pharmaceutical companies in the region and the growing interest in targeted therapies for cancer and other diseases. The dominant players in the North American PROTACs market include Arvinas, C4 Therapeutics, Nurix, and Kymera Therapeutics. These companies are focused on developing PROTACs for a wide range of indications, including cancer, inflammatory diseases, and neurodegenerative diseases. Arvinas, in particular, has been successful in advancing its lead PROTAC candidate, ARV-110, for the treatment of prostate cancer, and has entered into a partnership with Pfizer for the development of additional PROTAC candidates. The North American PROTACs market is also characterized by a large number of academic and research institutions that are focused on developing new PROTACs and advancing the understanding of protein degradation as a therapeutic modality. For example, the University of Michigan has developed a novel class of PROTACs that target the androgen receptor for the treatment of prostate cancer, while the University of California, San Francisco is focused on developing PROTACs for the treatment of HIV.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Protein Therapeutics Market
Buy Now GET FREE SAMPLE
Targeted Therapeutics Market
Buy Now GET FREE SAMPLE
Peptide Therapeutics Market
Buy Now GET FREE SAMPLE
Proteomics Market
Buy Now GET FREE SAMPLE
Targeted Protein Degradation Market
Buy Now GET FREE SAMPLE
Cancer Therapeutics Market
Buy Now GET FREE SAMPLE
Protein Engineering Market
Buy Now GET FREE SAMPLE
Research Antibodies and Reagents Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Proteolysis-targeting chimeric molecules (PROTACs) Market
Proteolysis-targeting chimeric molecules (PROTACs) Market

Report ID: SQMIG35I2121

sales@skyquestt.com
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE